Bausch Health is a corporate entity forever defined by its previous, toxic incarnation: Valeant Pharmaceuticals. For a brief period in the mid-2010s Valeant was the most celebrated, valued pharmaceutical company on Wall Street. Under the leadership of CEO J. Michael Pearson (a former McKinsey consultant), the company executed a radical, brutal business model. Pearson argued that traditional pharmaceutical R&D (spending billions trying to invent new drugs) was a terrible use of capital. Instead, Valeant operated as a ruthless "rollup" machine. It borrowed billions of dollars to acquire smaller companies that owned the rights to older, niche, essential drugs.
The Price-Gouging Engine
Once Valeant acquired a drug, the strategy was simple: immediately fire the entire R&D department of the acquired company to slash costs, and then astronomically raise the price of the drug. In some cases, Valeant acquired life-saving heart medications (like Isuprel and Nitropress) and immediately raised their prices by 500% or even 2000% overnight. Because patients had no alternative, they (and their insurance companies) were forced to pay. Wall Street analysts praised the strategy, driving Valeant's stock price to astronomical heights and making it briefly the most valuable company in Canada.
The Philidor Scandal and the Collapse
The, leveraged house of cards violently collapsed in 2015. Investigative journalists and aggressive short-sellers revealed that Valeant was using a secretive, captive network of specialty pharmacies (specifically a company called Philidor) to steer patients toward Valeant's overpriced drugs and essentially circumvent the cost-controls of major insurance companies. The revelation triggered a formidable political firestorm. Politicians held congressional hearings explicitly condemning Valeant's price-gouging. The company was investigated by the SEC for accounting fraud, major insurers refused to cover their drugs, and the stock price cratered by over 90%, destroying billions of dollars in shareholder value in a matter of months.
The Papa Turnaround and Rebranding
In 2016, facing imminent bankruptcy and crushed by a staggering $30 billion in debt, the board ousted Pearson and brought in Joseph Papa to execute a desperate rescue. Papa executed a, painful corporate triage. He sold off valuable assets (like the CeraVe skincare brand to L'Oréal) simply to raise the cash needed to make the interest payments on the debt. In 2018, desperately attempting to erase the toxic legacy of Valeant, the company officially changed its name to Bausch Health Companies, leaning on the prestigious, trusted legacy of its Bausch + Lomb eye care division.
The Bausch + Lomb Spinoff Struggle
Today, Bausch Health is essentially a considerable, complex financial hostage to its own history. The company still carries a burden of legacy debt. To finally unlock value, the company announced a formidable strategic plan to spin off Bausch + Lomb (which makes contact lenses and surgical equipment) into an entirely independent, publicly traded company. The logic is that the stable, respected eye care business is being severely undervalued while trapped inside the indebted parent company. However, executing this spin-off has been complex and delayed, entangled in significant legal battles over the patents for its gastrointestinal drug (Xifaxan), proving that escaping the toxic financial engineering of the Valeant era is a decade-long ordeal.
